Bristol-Myers Will Divest Celgene Blockbuster to Close Deal




 

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to divest one of Celgene Corp.'s most lucrative drugs in order to close their planned $74 billion merger.

Under an agreement with the Federal Trade Commission, Bristol-Myers will sell off the psoriasis pill Otezla to appease antitrust regulators' concerns, the company said in a statement.

Bristol-Myers shares fell as much as 7% to $45.89 in New York, the biggest intraday drop since the deal was announced on Jan. 3. Celgene declined as much as 4.7% to $94.26.

Otezla is a major product for Celgene, bringing in $1.86 billion last year, and was seen as an important driver of future growth as the two companies knit together their businesses. Bristol-Myers has been battling Merck & Co. for dominance in the field of cancer immunotherapy, while Celgene's blockbuster Revlimid for blood cancers is expected to face lower-priced competitors in coming years.

Otezla has as much as a decade of strong sales ahead, according to analysts' estimates surveyed by Bloomberg. Now, a rival drugmaker will get the rights to the pill, potentially at a discounted price. Johnson & Johnson's Janssen unit has said it's interested in pursuing an oral psoriasis treatment through an acquisition or its own pipeline.

Bristol-Myers is researching another type of therapy for psoriasis known as a TYK2-inhibitor that would likely compete with Celgene's blockbuster drug. While the drugs work differently, the overlap raised concerns from regulators, according to the statement. By divesting Otezla, Bristol-Myers is electing to sell a blockbuster in favor of a promising, though still experimental, therapy.

"Divesting Otezla a surprise to us and removes one of the newco's growth drivers," Vamil Divan, an analyst with Credit Suisse Group AG, said in a note to clients.

Taking Longer

Bristol-Myers also said that the deal will take longer to close than it had expected. Its new target is the end of 2019 or early 2020, pushed back from a previous goal of Sept. 30. The FTC review is ongoing, the company said, and European regulators will review it as well.

"Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene," the company said in the statement. It plans to use the proceeds to pay off debt.

The increased oversight spooked investors in another biotechnology company facing regulatory review. Earlier this month, the FTC requested more information about Spark Therapeutics Inc.'s proposed sale to Roche Holding AG, sending the gene therapy company's shares falling. Spark's shares dropped as much as 3.6% to $101.25 on the news of the Otezla divestiture.

In a research note, Jefferies analyst Michael Yee said it remains to be seen what the news could mean for the industry.

"We continue to be mindful and are carefully watching to get a better handle on if we are in a more aggressive FTC era for biotech," he wrote in a note to clients.

Separately, Bristol-Myers said that its cancer drug Opdivo, its No. 2 product, had failed a clinical trial treating liver cancer patients. The medicine faces multiple competitors that use the same mechanism to help the immune system attack tumors, and Bristol-Myers' rivals have been attempting to get the drugs approved in as many different types of cancer as possible.

(Updates with details about Bristol-Myers's psoriasis treatment in fourth paragraph.)

To contact the reporters on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.net

To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Mark Schoifet, Timothy Annett

For more articles like this, please visit us at bloomberg.com

©2019 Bloomberg L.P.

COMMENTS

More Related News

Harley Halts Output of Electric Model Pivotal to Revival Bid
Harley Halts Output of Electric Model Pivotal to Revival Bid

(Bloomberg) -- Harley-Davidson Inc. has halted production of LiveWire, the debut electric bike it's counting on to attract new riders.The motorcycle maker recently discovered an issue during final quality checks, according to an emailed statement that doesn't provide details. Harley said it stopped production

Johnson Stumbles in Bid for Brexit Deal as EU Demands Answers
Johnson Stumbles in Bid for Brexit Deal as EU Demands Answers
  • World
  • 2019-10-14 05:43:22Z

(Bloomberg) -- Sign up to our Brexit Bulletin, follow us @Brexit and subscribe to our podcast.Boris Johnson's attempt to secure a Brexit deal ran into trouble after the European Union warned the talks were still a long way from a breakthrough and the British prime minister's political allies distanced themselves from his plans. The pound fell. After a weekend of intensive negotiations in Brussels, the EU's chief Brexit negotiator, Michel Barnier, told a meeting of envoys on Sunday that the U.K.'s proposals for breaking the deadlock over the Irish border lacked detail and risked leaving the single market vulnerable to fraud, officials said. The unionist party that backs Johnson's minority...

Billionaires Could Face Tax Rates Up to 97.5% Under Sanders
Billionaires Could Face Tax Rates Up to 97.5% Under Sanders

(Bloomberg) -- Billionaires may have much more to fear from a Bernie Sanders presidency than they do from an Elizabeth Warren administration, according to two economists advising both candidates.That's one of the conclusions of a new interactive website developed by University of California, Berkeley professors Emmanuel Saez and Gabriel Zucman.If Sanders had his way, they calculate that the 400 richest Americans, on average, would have an effective tax rate of 97.5%. That includes not only their income, but also a wealth tax that whittles away at the family fortune.The 97.5% average effective tax rate under his plans compares with 23% now and 62% under Warren's proposals, according to the...

China Denied U.S. Lawmakers Visas Over Taiwan Visit
China Denied U.S. Lawmakers Visas Over Taiwan Visit

(Bloomberg) -- China denied entry visas to a U.S. congressional delegation, with Chinese officials telling one congressman's staff members the visas would be granted for their trip only if they canceled a stop in Taiwan.Representative Sean Patrick Maloney, a New York Democrat, said in a Wall Street Journal op-ed that the quid pro quo amounted to "visa blackmail, designed to stanch the longstanding tradition of robust U.S. congressional engagement with Taiwan."Maloney warned Beijing that "ham-handed and obtusely enforced pressure campaigns" will only "invigorate congressional support for Taiwan." He said he will be exploring ways for Congress to "reinforce U.S. support for Taiwan" in the...

Schiff Says Secret Testimony Aimed at Keeping Trump in the Dark
Schiff Says Secret Testimony Aimed at Keeping Trump in the Dark

(Bloomberg) -- House Intelligence Committee Chairman Adam Schiff defended holding testimony behind closed doors in the impeachment inquiry he's heading up against President Donald Trump, likening this phase of the investigation to a "grand jury.""We want to make sure that we meet the needs of the investigation and not give the president or his legal minions the opportunity to tailor their testimony and in some cases fabricate testimony to suit their interests," the California Democrat said Sunday on CBS's "Face the Nation."Schiff said they may call some or all of the witnesses to return to testify in public later, though that might not include the whistle-blower who triggered the...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Economy

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.